Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Clin Cancer Res. 2016 Nov 30;23(11):2795–2805. doi: 10.1158/1078-0432.CCR-15-2764

Fig. 2.

Fig. 2

Combined targeting of p110α/β abrogates growth in anti-estrogen-sensitive and -resistant, PTEN-deficient, ER+ breast cancer cells. A) Parental cells were treated with 1 μM fulv, 1 μM BYL719, 1 μM GSK2636771, or combinations. Medium and drugs were replenished every 3 days. When control wells reached 50-70% confluence (after 20-40 d), cells were stained with crystal violet. Quantification is shown as mean of triplicates + SD (% control). B) FR cells were analyzed as in (A). *p<0.05 by Bonferroni post-hoc test compared to control, unless otherwise indicated with brackets.